AMENDMENTS TO THE CLAIMS:

Pursuant to the requirements for a Reissue Application according to 37 CFR § 1.173(b)(2) and further to the requirement stated in the Final Office Action that Applicant provide a "clean copy of all new claims (those not issued in the patent) - with underlining," without prejudice or disclaimer, please amend the claims according to the following listing:

- 1 6 Cancelled
- 7. (Amended) A method of decreasing <u>a risk of</u> mortality caused by congestive heart failure in a patient, said method comprising administering to said patient first dosages once or twice daily, for a period of from 7 to 28 days, said first dosages each comprising carvedilol in an amount of about 3.125 mg or 6.25 mg,

then administering to said patient second dosages once or twice daily,

for a period of from 7 to 28 days, said second dosages each comprising

carvedilol in an amount of about 12.5 mg, and

then administering to said patient maintenance third dosages once or twice daily, said third dosages each comprising carvedilol in an amount of about 25.0 mg or about 50.0 mg.

- 9. Cancelled
- 12 15 Cancelled
- 16. A method according to claim 7, wherein said patient has class II-IV congestive heart failure.
 - 17 Cancelled
 - 18 Cancelled

- 19. A method according to claim 10, wherein said patient has class II-IV congestive heart failure.
- 20. A method of decreasing a risk of mortality caused by congestive heart failure in a patient, said method comprising administering to said patient first dosages once or twice daily, for a period of from 7 to 28 days, said first dosages each comprising carvedilol in an amount of about 3.125 mg,

then administering to said patient second dosages once or twice daily, for a period of from 7 to 28 days, said second dosages each comprising carvedilol in an amount of about 12.5 mg, and

then administering to said patient maintenance third dosages once or twice daily, said third dosages each comprising carvedilol in an amount of about 25.0 mg or about 50.0 mg.

- 21. A method as recited in claim 20, further comprising, after administering the first dosages and before administering the second dosages, administering to said patient intermediate dosages once or twice daily, for a period of from 7 to 28 days, said intermediate dosages each comprising carvedilol in an amount of about 6.25 mg.
 - 22 Cancelled
 - 23 Cancelled
- 24. A method according to claim 20, wherein said patient has class II-IV congestive heart failure.
- 25. A method as recited in claim 20, wherein at least one of said first, second and maintenance dosages further comprises at least one other therapeutic agent

selected from the group consisting of an angiotensin converting enzyme inhibitor, a diuretic and a cardiac glycoside.

26 - 30 Cancelled